| Description | Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration. |
| In vivo | Ciamexon对BB大鼠糖尿病发展的影响研究表明，从42天或50天开始至120天，每周6天每天给药一次。作为对比，按照相同协议应用Cyclosporin A（10 mg/kg）。在1 mg/kg的剂量下，Ciamexon的给药完全防止了雌性大鼠的糖尿病，但对雄性大鼠无益。10 mg/kg的剂量则显著抑制了雄性大鼠的糖尿病发展，对雌性大鼠的效果更为明显。在雌性大鼠中观察到糖尿病发生率的降低和高血糖发生的延迟。Cyclosporin A的给药后，所有动物均未发展成糖尿病。Ciamexon治疗未影响周围血液中的粒细胞和淋巴细胞计数及亚群，除了有抑制嗜酸性粒细胞增多的趋势。动物的生长未受阻碍。因此得出结论，Ciamexon似乎影响BB大鼠的自身免疫状态，导致疾病的部分抑制。 |
| Synonyms | Ciamexone, BM 41332, BM41332, BM-41332 |
| molecular weight | 203.24 |
| Molecular formula | C11H13N3O |
| CAS | 75985-31-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 55 mg/mL (270.62 mM) |
| References | 1. Kiesel U, et al. Suppression of spontaneous insulin-dependent diabetes in BB rats by administration of ciamexone. J Immunopharmacol. 1986;8(3):393-406. |